Remove Cosmetics Remove Licensing Remove Marketing Remove Sales
article thumbnail

Ipsen plans sale of consumer health business for €350m

pharmaphorum

Privately-held Mayoly Spindler is a specialist in gastroenterology and dermato-cosmetic products that has set itself the target of becoming a top 10 European OTC medicines company in the next 10 years. The post Ipsen plans sale of consumer health business for €350m appeared first on. billion takeover of Clementia Pharma in 2019.

Sales 103
article thumbnail

Crescita Announces Licensing Agreement for Pliaglis; in China

The Pharma Data

Ltd (“Juyou”), a biotechnology company that develops and sells medical and cosmetic skincare products, for the commercialization and development of Pliaglis ® in mainland China (the “License Agreement”). million and US$1.8 About Juyou Bio – Technology Co. Juyou Bio-Technology Co.,

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The Wholesaling Prohibition (Potentially) Demystified? FDA’s Take on Supply Chains for Section 503B Outsourcing Facilities

FDA Law Blog

Palmer — Last week FDA published a long-awaited Draft Guidance for outsourcing facilities addressing the Prohibition on Wholesaling Under Section 503B of the Federal Food, Drug, and Cosmetic Act (Draft Guidance). An area of clarification that we believe will be appreciated by industry concerns sales to a group purchasing organization (GPO).

Drugs 52
article thumbnail

Papa Can You Hear Me? Now You Can Thanks to OTC Hearing Aids

FDA Law Blog

Thus, only self-fitting hearing aids need to be cleared by FDA prior to marketing; regular OTC hearing aids—ones that are customizable based on user preference—do not, and consumers must rely on FDA postmarket enforcement activities to ensure safety and effectiveness of OTC hearing aids (more on that later).

article thumbnail

Biosimilars vs. Interchangeable Biological Products: FDA Fact Check

XTalks

As biologics have the reputation of being expensive due to their complex nature and production, biosimilars have the ability to improve market access to patients and payors who would otherwise be unable to afford these drugs. To date, the FDA has approved 29 biosimilars, 19 of which are currently being marketed.

article thumbnail

Tauriga Sciences Inc. Sets New Daily E-Commerce Records for Both: Revenue Generated [$9,514.49] and Individual Online Orders [103 Total]

The Pharma Data

in Daily E-Commerce Sales and recorded 103 individual E-Commerce Order Transactions (average order size: $92.37). We have also launched several new product offerings, most notably a dark chocolate coin (each infused with 20mg CBD) and some skin care/cosmetics selections. On Wednesday, November 25, 2020, the Company generated $9,514.49

article thumbnail

Surely You Must be Kidding, PTO?!? “No, and Don’t Call Me Shirley!” – The Seemingly Slapstick (But Yet Unfunny) World of Recent Patent Term Extension Decisions (PART 2)

FDA Law Blog

If the confirmatory trial does not show that the drug provides clinical benefit, FDA has regulatory procedures in place that could lead to removing the drug from the market. 156 or case law that would support extension of the ‘929 patent that claims the product despite revocation of the biologics license application.